+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Reassortant Avian Influenza Virus Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

  • PDF Icon

    Report

  • 150 Pages
  • November 2026
  • Region: Global
  • Lucintel
  • ID: 6293476
The global reassortant avian influenza virus vaccine market is expected to reach an estimated $37.4 billion by 2035 from $19.2 billion in 2027 with a CAGR of 8.9% from 2027 to 2035. The major drivers for this market are the increasing outbreaks of avian influenza, growing government initiatives for poultry vaccination, and advances in vaccine development for broader protection against multiple strains.

The future of the global reassortant avian influenza virus vaccine market looks promising with opportunities in the piglets, adults pigs markets.
  • Within the type category, trivalent inactivated vaccine is expected to witness higher growth over the forecast period due to offering more comprehensive immunity compared to the bivalent version.
  • Within the application category, piglets is expected to witness the higher growth due to more susceptible to infections like mycoplasma hypermania.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to high poultry population, frequent avian influenza outbreaks.

Emerging Trends in Reassortant Avian Influenza Virus Vaccine Market

The market for the reassortant avian influenza virus vaccine is shifting from emergency response to a preparedness system to be implemented throughout the year. During the period of 2025-2027, governments, poultry producers, and veterinary suppliers will pay special attention to the speed of updates of strain variability, the range of protection and the scale of production. According to Lucintel, purchasing decisions will favor significant regulatory progress, greater resilience of production, and evidence of use of the vaccine in the field.
  • Adaptability of Strains: Reassortment of avian influenza viruses continues to receive focus, and the WHO has informed that as Drift of viruses occurs, the useful life of fixed compositions gets shorter. Hence, systems that can rapidly replace antigens will be of great significance.
  • Poultry Vaccination Programs: Different countries are shifting from simply culling-based control to targeted vaccination of poultry, and the national vaccination program of France is expected to cover millions of ducks in the 2024-2025 Program. This trend is expected to increase demand of veterinary products that are efficient and of low-cost and high throughput.
  • Surveillance: DIVA vaccination is of great focus, and to improve trade relations, there is a focus on improving vaccine technology and surveillance that can distinguish vaccine responses from field infections. This will influence the voting pattern since there is a great demand for vaccination technology that does not lose the disease free status.
  • Manufacturing Scale: The United States Government allocated USD 100 million to avian influenza preparedness and response in 2025, which demonstrates the importance of surge capacity. During the next 5 years, flexibility of filling and finishing, regional stockpiles and shorter production will become important considerations for purchase.
  • One Health Surveillance: Recent findings in poultry, wild birds, and mammals have challenged the relationship between public health and veterinary medicine. The USDA has estimated over 130 million affected poultry by 2025. Integrated data will help select the most appropriate strain and minimize vaccine-virus mismatches.
It is expected that governments will give more value to AVI vaccines between 2025 and 2027 as the focus will be more on preparedness, speed of vaccine updates, and the increased flexibility of vaccine production. There will continue to be significant fluctuations in demand based on the fact that their budgets are very limited and within a few months the demand and focus will be diverted to other priorities. Manufacturers who cross the barriers of regulatory compliance and secure capacity should capture a significant share of this market. Product differentiation will be based primarily on evidence.

Recent Developments in the Reassortant Avian Influenza Virus Vaccine Market

The market for the reassortant avian influenza virus vaccine is moving from purely defensive planning in the majority of countries to selective market deployment. During the period 2025-2027, activities will expand in the areas of field trials, the regulatory pathways, regional manufacturing, and trade-restrictive vaccination programs. According to Lucintel, purchasing behavior will continue to be heterogenous as governments attempt to balance flock protection with surveillance and export needs.
  • Expansion of Public Funding: In March 2025, the U.S. Department of Agriculture disclosed the allocation of $1 billion toward strengthening the response to H5N1 and related preparedness and vaccine R&D. Vaccine R&D using reassortant technology is expected to be improved and accelerated during the next 3 to 5 years.
  • Increased Field Testing: Within the 2025 field testing policy, the USDA-APHIS allowed poultry vaccine field studies. Evidence is needed on the impact of shedding, productivity, and alternative differentiation before regulations and production are authorized to support broad flock vaccination.
  • Regional Production Focus: In 2025, investment in regional vaccine manufacturing was an area of increased focus among vaccine producers after multiple HPAI outbreaks and associated supply disruptions. While regional manufacturing will affect vaccine market shares, it can provide a rapid response to a localized outbreak.
  • National Vaccination Programs: The 2025-2026 vaccination campaign was supported by the French government, and continued the national vaccination campaign for ducklings. Over 60 million vaccine doses had been administered during the previous campaign. Governments will create demand, and supply and surveillance constraints will be tested.
  • DIVA Technology: Focus for 2025 is on marker vaccines and companion diagnostic development. Concerns about vaccine export have driven such work. Surveillance credibility and blanket trade restrictions concerns can be addressed with products that identify either vaccinated or infected animals. Such tools can promote greater vaccine uptake.
Client demand has transitioned from emergency flock protection toward products that safeguard the trade and are differentiating. Regulatory approval will determine market penetration more than the performance of the assays in the lab. Vendors with a rapid and flexible approach to manufacturing, surveillance, and DIVA should gain the most market share. For the foreseeable future, until national policies and export markets stabilize, purchasing will continue to be sporadic, favoring flexible localized production.

Strategic Growth Opportunities in the Reassortant Avian Influenza Virus Vaccine Market

The reassortant avian influenza virus vaccine market is gaining commercial attention. Governments are likely to consider new prevention policies for poultry as the risk of poultry loss increases due to frequent H5 outbreaks. Surveillance and trade control improvements, coupled with increasing concerns about food supply protection from 2024 to 2026, are expected to drive the market. Based on its analyses, Lucintel sees market potential beyond emergency stockpiling in locations where vaccination could prevent production disruptions.
  • Commercial Poultry Vaccination: According to the 2025 U.S. poultry industry report, 130 million poultry were affected by 2025. With the metering of reassortant vaccines, improved integrator mortality and depopulation events can be expected.
  • Dairy-cattle Applications: By March 2025, H5N1 was confirmed to be affecting 989 U.S. dairy cattle. Regulatory agencies’ focus on milk safety and farm productivity create opportunities for dairy-cattle focused vaccinations and controlled vaccination programs.
  • Premium DIVA Products: As of February 2025, WOAH documented that trade acceptance is significantly influenced by the ability of testing to distinguish between vaccinated and infected animals. DIVA vaccination technology will likely charge a premium, given that their use supports surveillance and export trade.
  • Geographic Expansion: Human cases of H5N1 in Vietnam in 2025 further expands Northeast Asia’s exposure. Local manufacturing partnerships together with regional regulatory dossiers enhance the ability to sell vaccines in markets with dense poultry.
  • Digital Manufacturing and Analytics: In June 2025, FAO’s EMPRES-I platform recorded over 1,000 global avian influenza cases. Producers coupling predictive vaccination with genomic surveillance help reduce waste and improve value stream selection.
There will be a shifting focus of demand from emergency procurement to risk management of disease. Suppliers that provide cover across livestock (poultry and cattle) and provide flexibilization of trade and of production remain the preferred suppliers for longer contracts. The other supply side determinants remain the same. Premium markets will also pay for rapid changes to strains and for assurances of traceability. The focus of production is expected to be regional, although as expected there will be more emphasis on steady growth.

Reassortant Avian Influenza Virus Vaccine Market Drivers and Challenges

Technology, changing disease patterns, economic factors, and evolving regulations will affect the future of the reassortant avian influenza virus vaccine market. Demand will increase as pandemic preparedness will improve, manufacturers will develop more adaptable vaccines, and governments and farmers will adopt protective measures. Lucintel considers innovation, production, surveillance, and affordability the major factors. Regulation, mutation of viruses, development disparities and uncertainty of vaccination policies will affect the commercialization, procurement and market expansion.

The factors responsible for driving this market include:

  • Increased Risk of Outbreak: There has been an increase in reports of highly pathogenic avian influenza in both poultry and wild birds. This has LED to many governments increasing their preparedness programs. In January 2025, the World Organization for Animal Health reported outbreaks in many regions. This resulted in the need for vaccines to be deployed more quickly and in the need for more emergency stockpiles. Reassortant vaccines can be adapted to the changing circulating strains more quickly and therefore can be utilized during an outbreak. It is expected that in the next three to five years, there will be a demand for flexible vaccines due to persistent animal outbreaks and occasional zoonotic infections, but the procurement may be more concentrate in the countries that have a large poultry industry and better veterinary systems.
  • Innovations in Reverse Genetics, Antigen Selection, and Adjuvant Systems: Better reverse genetics, antigen selection, adjuvant systems, and molecular surveillance continue to enhance the speed and precision of designing reassortant vaccines. In February 2025, global health organizations continued assessments of candidate influenza viruses to enhance pandemic preparedness and vaccine alignment. Technologies continue to improve to focus on producing viral strains that more closely match circulating wild viruses while maintaining a scalable approach to manufacturing. Over the next three to five years, improvements to sequencing and laboratory automation will further reduce the development time for effective vaccines and focus on producing more specialized vaccines for poultry as well as targeting human health. However, the impact of these advancements will depend on validation and biosafety systems, and the capability of the companies to transform research processes for vaccination to a commercial reality.
  • Increased Government Preparedness and Regulatory Flexibility: Governments are being more prepared and are facilitating more frequent surveillance and greater acquisition of food supply insurance and public health vaccines. Avian influenza is a huge threat to the food supply as well as international trade. In 2025, March, several countries that had recently experienced outbreaks of avian influenza amongst their poultry, continued intensified surveillance coupled with a simultaneous response. Regulatory systems are also more prepared to focus on changes to the influenza vaccination where rapid shifts occur in influenza strains. In the next three to five years, there will be more funding and more targeted vaccination priorities coupled with a decreased time for approval. There will be more challenges to the global marketplace including differentiated vaccine policies, export differentiation, and control for infected vs. vaccinated animals.
  • Poultry Industry Demand: Commercial poultry producers experience losses from mortality and production disruption when high numbers of birds succumb to disease. Losses are further compounded by trade disruptions and the cost of restocking. As a result of these ongoing costs, commercial producers need alternative solutions to mass culling. In April 2025, outbreaks in poultry production regions demonstrated the financial risks for farms and production facilities from the lack of continuous supply. Reassortant vaccines, if used along with biosecurity and disease surveillance, can slow circulation of viruses and help protect breeding and laying birds. The next three to five years should show an increased use of this technology in situations where vaccination does not contravene trade laws and where monitoring systems are in place. This technology is expected to be most used in regions with high population densities, but producers may still resist this technology due to increased costs and production complexity.
  • Manufacturing Efficiency and Product Innovation: The dependence on the traditional embryonated egg system can be lessened through the use of cell-based technologies, advanced bioreactors, and improved adjuvant systems. In May 2025, the continued expansion of worldwide production of influenza vaccines demonstrated the need for multiple production technologies. Reassortant technologies can be used to develop vaccines targeted to specific age groups of poultry and can be tailored to differing poultry species and regional diversity of viruses. In the next three to five years, innovation in manufacturing is expected to make the supply of vaccines more reliable, to lower the cost of each unit, and to speed up production, if uninterrupted supply and biosafety are maintained.

The challenges facing this market include:

  • Viral Mutation and Vaccine Matching: The mutation and reassortment of avian influenza viruses lead to limitations of vaccines. When the vaccine strains and the circulating strains of viruses no longer match, protection may be reduced. In June 2025, the genetically diverse forms of H5 and H7 viruses were identified through ongoing surveillance in bird populations. It was clear that developing an effective vaccine was nearly impossible. Manufacturers have to continually update their antigens and conduct additional efficacy studies, which cost time and money. Unpredictable rapid viral evolution will be the major constraint over the next three to five years. This will require a step-change in genomic surveillance, flexibility in production, and improved data sharing. Poor matching will diminish confidence of producers and will discourage participation in routine vaccination programs.
  • Regulatory and Trade Barriers: Vaccine decisions are often made in concert with animal health regulations and the ability of countries to distinguish vaccinated animals from infected animals. Trading animals. In July 2025, it was clear that different countries employed different policies for vaccination, movement control, and surveillance during their avian influenza outbreaks. This variability delayed approvals and constrained exports of vaccinated regions, discouraging poultry producers from using the available products. It is anticipated that during the next three to five years, the market will require the development of harmonized international testing and product standards, and more clearly defined market compartments. Unless there is harmonization of regulation, manufacturers may face a fragmented market, duplicated assessments, and lengthy approval periods.
  • High Costs and Uneven Infrastructure: The validation, manufacturing, delivery, administration, and monitoring of post-vaccination response create high costs for vaccine implementation. Smaller producers and lower income countries are even more challenged. By August 2025, many regions producing poultry were still using a combination of surveillance, culling, and movement control, as comprehensive infrastructure for vaccine delivery was lacking. Thus, it is likely that reassortant vaccines will continue to be delivered to high net worth markets with well-developed veterinary services and the capacity to produce vaccines. Affordability will be as important as technical performance in the next 3-5 years to determine the use of vaccines. Governments and the vaccine industry will need to create financing programs, establish regional production, training, and integrated delivery to overcome the lack of infrastructure and ensure that new market opportunities are not constrained.
Vaccine innovation is encouraged by the technical shortcomings of existing vaccines, the threat of outbreaks, awareness of the need for public preparedness, and the continued financial losses incurred by the uncertainty of the poultry industry. Faster and broader protection from vaccines is enhanced by innovative vaccine platforms and improved surveillance coupled with shorter vaccine manufacturing lead times. The high costs and complex approvals coupled with trade restrictions, uneven veterinary capacity, and the evolution of viruses create barriers for widespread adoption of the vaccines. In the next 3-5 years it is anticipated that the performance of the market will be a function of integrated regulation, sustained public investment, affordable production, and integration of vaccination with biosecurity and surveillance and control programs.

List of Reassortant Avian Influenza Virus Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies reassortant avian influenza virus vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the reassortant avian influenza virus vaccine market companies profiled in this report include:

  • Zoetis
  • Boehringer-Ingelheim
  • Eurovet
  • Merck Animal Health
  • Bicr
  • China Animal Husbandry Industry
  • Weike Biotechnology
  • Ringpu
  • Guangdong Winsun Bio Pharmaceutical
  • Pulike

Reassortant Avian Influenza Virus Vaccine Market by Segment

The study includes a forecast for the global reassortant avian influenza virus vaccine market by type, application, and region.

Type [Value ($B) from 2019 to 2035]:

  • Bivalent Inactivated Vaccine
  • Trivalent Inactivated Vaccine

Application [Value ($B) from 2019 to 2035]:

  • Piglets
  • Adults Pigs

Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Reassortant Avian Influenza Virus Vaccine Market

Increased government engagement on poultry biosecurity, vaccine readiness, and controlled field use defines the current market for the reassortant avian influenza vaccine. From 2025 to 2027, national responses will focus on conditional approvals, funding for research, antigen matching, and trade-related vaccination policies. For 2021-2027, the policy implementation phase will be the most crucial, according to Lucintel.
  • United States: Federal funding for vaccines the USDA’s United States Department of Agriculture allocated $100 million for avian influenza vaccine development in February 2025, within a larger $1 billion response package. APHIS was also in discussions with manufacturers regarding H5 vaccine candidates. This is important, because, in the next 3 to 5 years, with federal funding and regulatory efforts, reassortant products can be moved from the laboratory to poultry for controlled deployment.
  • China: Mandatory vaccination Infrastructure China’s Ministry of Agriculture and Rural Affairs mandated H5/H7 poultry vaccinations for 2025, while domestic manufacturers produced bivalent inactivated vaccines. This is important, because mandatory vaccinations and large-scale manufacturing provide the market’s most consistent demand.
  • Germany: Containment policy Germany implemented the EU’s 2023 vaccination policy while the Friedrich Loeffler Institute continued to perform surveillance and evaluate vaccines. The European Commission reported 1,298 avian influenza outbreaks in captive birds during the 2024-2025 season (June 2025). This is important because Germany’s vaccination policy will determine if the trade remains uninterrupted.
  • India: The Indian government's response was controlling and tracking the spread of the disease and conducting culling operations when outbreaks occurred in 2025. Kerala reported more than 100,000 birds having been culled in April 2025. This is important because any potential vaccine authorization will have to be able to facilitate rapid culling, while also considering export restrictions and the safety of the food supply.
  • Japan: Biosecurity based policy Japan's agriculture ministry notified existence of 51 highly pathogenic avian-influenza outbreaks in poultry farms during the 2024-2025 season (May 2025) and ordered country-wide surveillance and culling. This is important because repeated outbreaks and Japan's concentrated layer and broiler production are likely to encourage government to support policy for the purposeful use of vaccines.

Features of the Global Reassortant Avian Influenza Virus Vaccine Market

  • Market Size Estimates: reassortant avian influenza virus vaccine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: reassortant avian influenza virus vaccine market size by type, application, and region in terms of value ($B).
  • Regional Analysis: reassortant avian influenza virus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the reassortant avian influenza virus vaccine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the reassortant avian influenza virus vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the reassortant avian influenza virus vaccine market by type (bivalent inactivated vaccine and trivalent inactivated vaccine), application (piglets and adults pigs), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.1 Global Reassortant Avian Influenza Virus Vaccine Market Trends and Forecast
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Reassortant Avian Influenza Virus Vaccine Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Bivalent Inactivated Vaccine: Trends and Forecast (2019-2035)
4.4 Trivalent Inactivated Vaccine: Trends and Forecast (2019-2035)
5. Global Reassortant Avian Influenza Virus Vaccine Market by Application
5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Piglets: Trends and Forecast (2019-2035)
5.4 Adults Pigs: Trends and Forecast (2019-2035)
6. Regional Analysis
6.1 Overview
6.2 Global Reassortant Avian Influenza Virus Vaccine Market by Region
7. North American Reassortant Avian Influenza Virus Vaccine Market
7.1 Overview
7.2 North American Reassortant Avian Influenza Virus Vaccine Market by Type
7.3 North American Reassortant Avian Influenza Virus Vaccine Market by Application
7.4 United States Reassortant Avian Influenza Virus Vaccine Market
7.5 Mexican Reassortant Avian Influenza Virus Vaccine Market
7.6 Canadian Reassortant Avian Influenza Virus Vaccine Market
8. European Reassortant Avian Influenza Virus Vaccine Market
8.1 Overview
8.2 European Reassortant Avian Influenza Virus Vaccine Market by Type
8.3 European Reassortant Avian Influenza Virus Vaccine Market by Application
8.4 German Reassortant Avian Influenza Virus Vaccine Market
8.5 French Reassortant Avian Influenza Virus Vaccine Market
8.6 Spanish Reassortant Avian Influenza Virus Vaccine Market
8.7 Italian Reassortant Avian Influenza Virus Vaccine Market
8.8 United Kingdom Reassortant Avian Influenza Virus Vaccine Market
9. APAC Reassortant Avian Influenza Virus Vaccine Market
9.1 Overview
9.2 APAC Reassortant Avian Influenza Virus Vaccine Market by Type
9.3 APAC Reassortant Avian Influenza Virus Vaccine Market by Application
9.4 Japanese Reassortant Avian Influenza Virus Vaccine Market
9.5 Indian Reassortant Avian Influenza Virus Vaccine Market
9.6 Chinese Reassortant Avian Influenza Virus Vaccine Market
9.7 South Korean Reassortant Avian Influenza Virus Vaccine Market
9.8 Indonesian Reassortant Avian Influenza Virus Vaccine Market
10. RoW Reassortant Avian Influenza Virus Vaccine Market
10.1 Overview
10.2 RoW Reassortant Avian Influenza Virus Vaccine Market by Type
10.3 RoW Reassortant Avian Influenza Virus Vaccine Market by Application
10.4 Middle Eastern Reassortant Avian Influenza Virus Vaccine Market
10.5 South American Reassortant Avian Influenza Virus Vaccine Market
10.6 African Reassortant Avian Influenza Virus Vaccine Market
11. Competitor Analysis
11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter’s Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
11.4 Market Share Analysis
12. Opportunities & Strategic Analysis
12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
12.2.1 Growth Opportunities by Type
12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Reassortant Avian Influenza Virus Vaccine Market
12.4 Strategic Analysis
12.4.1 New Product Development
12.4.2 Certification and Licensing
12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures
13. Company Profiles of the Leading Players Across the Value Chain
13.1 Competitive Analysis
13.2 Zoetis
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.3 Boehringer-Ingelheim
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.4 Eurovet
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.5 Merck Animal Health
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.6 Bicr
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.7 China Animal Husbandry Industry
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.8 Weike Biotechnology
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.9 Ringpu
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.10 Guangdong Winsun Bio Pharmaceutical
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.11 Pulike
  • Company Overview
  • Reassortant Avian Influenza Virus Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
14. Appendix
14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us
List of Figures
Chapter 1
Figure 1.1: Trends and Forecast for the Global Reassortant Avian Influenza Virus Vaccine Market
Chapter 2
Figure 2.1: Usage of Reassortant Avian Influenza Virus Vaccine Market
Figure 2.2: Classification of the Global Reassortant Avian Influenza Virus Vaccine Market
Figure 2.3: Supply Chain of the Global Reassortant Avian Influenza Virus Vaccine Market
Chapter 3
Figure 3.1: Driver and Challenges of the Reassortant Avian Influenza Virus Vaccine Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Chapter 4
Figure 4.1: Global Reassortant Avian Influenza Virus Vaccine Market by Type in 2019, 2026, and 2035
Figure 4.2: Trends of the Global Reassortant Avian Influenza Virus Vaccine Market ($B) by Type
Figure 4.3: Forecast for the Global Reassortant Avian Influenza Virus Vaccine Market ($B) by Type
Figure 4.4: Trends and Forecast for Bivalent Inactivated Vaccine in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Figure 4.5: Trends and Forecast for Trivalent Inactivated Vaccine in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Chapter 5
Figure 5.1: Global Reassortant Avian Influenza Virus Vaccine Market by Application in 2019, 2026, and 2035
Figure 5.2: Trends of the Global Reassortant Avian Influenza Virus Vaccine Market ($B) by Application
Figure 5.3: Forecast for the Global Reassortant Avian Influenza Virus Vaccine Market ($B) by Application
Figure 5.4: Trends and Forecast for Piglets in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Figure 5.5: Trends and Forecast for Adults Pigs in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Chapter 6
Figure 6.1: Trends of the Global Reassortant Avian Influenza Virus Vaccine Market ($B) by Region (2019-2026)
Figure 6.2: Forecast for the Global Reassortant Avian Influenza Virus Vaccine Market ($B) by Region (2027-2035)
Chapter 7
Figure 7.1: North American Reassortant Avian Influenza Virus Vaccine Market by Type in 2019, 2026, and 2035
Figure 7.2: Trends of the North American Reassortant Avian Influenza Virus Vaccine Market ($B) by Type (2019-2026)
Figure 7.3: Forecast for the North American Reassortant Avian Influenza Virus Vaccine Market ($B) by Type (2027-2035)
Figure 7.4: North American Reassortant Avian Influenza Virus Vaccine Market by Application in 2019, 2026, and 2035
Figure 7.5: Trends of the North American Reassortant Avian Influenza Virus Vaccine Market ($B) by Application (2019-2026)
Figure 7.6: Forecast for the North American Reassortant Avian Influenza Virus Vaccine Market ($B) by Application (2027-2035)
Figure 7.7: Trends and Forecast for the United States Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 7.8: Trends and Forecast for the Mexican Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 7.9: Trends and Forecast for the Canadian Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Chapter 8
Figure 8.1: European Reassortant Avian Influenza Virus Vaccine Market by Type in 2019, 2026, and 2035
Figure 8.2: Trends of the European Reassortant Avian Influenza Virus Vaccine Market ($B) by Type (2019-2026)
Figure 8.3: Forecast for the European Reassortant Avian Influenza Virus Vaccine Market ($B) by Type (2027-2035)
Figure 8.4: European Reassortant Avian Influenza Virus Vaccine Market by Application in 2019, 2026, and 2035
Figure 8.5: Trends of the European Reassortant Avian Influenza Virus Vaccine Market ($B) by Application (2019-2026)
Figure 8.6: Forecast for the European Reassortant Avian Influenza Virus Vaccine Market ($B) by Application (2027-2035)
Figure 8.7: Trends and Forecast for the German Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 8.8: Trends and Forecast for the French Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 8.9: Trends and Forecast for the Spanish Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 8.10: Trends and Forecast for the Italian Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 8.11: Trends and Forecast for the United Kingdom Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Chapter 9
Figure 9.1: APAC Reassortant Avian Influenza Virus Vaccine Market by Type in 2019, 2026, and 2035
Figure 9.2: Trends of the APAC Reassortant Avian Influenza Virus Vaccine Market ($B) by Type (2019-2026)
Figure 9.3: Forecast for the APAC Reassortant Avian Influenza Virus Vaccine Market ($B) by Type (2027-2035)
Figure 9.4: APAC Reassortant Avian Influenza Virus Vaccine Market by Application in 2019, 2026, and 2035
Figure 9.5: Trends of the APAC Reassortant Avian Influenza Virus Vaccine Market ($B) by Application (2019-2026)
Figure 9.6: Forecast for the APAC Reassortant Avian Influenza Virus Vaccine Market ($B) by Application (2027-2035)
Figure 9.7: Trends and Forecast for the Japanese Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 9.8: Trends and Forecast for the Indian Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 9.9: Trends and Forecast for the Chinese Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 9.10: Trends and Forecast for the South Korean Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 9.11: Trends and Forecast for the Indonesian Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Chapter 10
Figure 10.1: RoW Reassortant Avian Influenza Virus Vaccine Market by Type in 2019, 2026, and 2035
Figure 10.2: Trends of the RoW Reassortant Avian Influenza Virus Vaccine Market ($B) by Type (2019-2026)
Figure 10.3: Forecast for the RoW Reassortant Avian Influenza Virus Vaccine Market ($B) by Type (2027-2035)
Figure 10.4: RoW Reassortant Avian Influenza Virus Vaccine Market by Application in 2019, 2026, and 2035
Figure 10.5: Trends of the RoW Reassortant Avian Influenza Virus Vaccine Market ($B) by Application (2019-2026)
Figure 10.6: Forecast for the RoW Reassortant Avian Influenza Virus Vaccine Market ($B) by Application (2027-2035)
Figure 10.7: Trends and Forecast for the Middle Eastern Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 10.8: Trends and Forecast for the South American Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Figure 10.9: Trends and Forecast for the African Reassortant Avian Influenza Virus Vaccine Market ($B) (2019-2035)
Chapter 11
Figure 11.1: Porter’s Five Forces Analysis of the Global Reassortant Avian Influenza Virus Vaccine Market
Figure 11.2: Market Share (%) of Top Players in the Global Reassortant Avian Influenza Virus Vaccine Market (2026)
Chapter 12
Figure 12.1: Growth Opportunities for the Global Reassortant Avian Influenza Virus Vaccine Market by Type
Figure 12.2: Growth Opportunities for the Global Reassortant Avian Influenza Virus Vaccine Market by Application
Figure 12.3: Growth Opportunities for the Global Reassortant Avian Influenza Virus Vaccine Market by Region
Figure 12.4: Emerging Trends in the Global Reassortant Avian Influenza Virus Vaccine Market
List of Tables
Chapter 1
Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Reassortant Avian Influenza Virus Vaccine Market by Type and Application
Table 1.2: Attractiveness Analysis for the Reassortant Avian Influenza Virus Vaccine Market by Region
Table 1.3: Global Reassortant Avian Influenza Virus Vaccine Market Parameters and Attributes
Chapter 3
Table 3.1: Trends of the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 3.2: Forecast for the Global Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Chapter 4
Table 4.1: Attractiveness Analysis for the Global Reassortant Avian Influenza Virus Vaccine Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 4.3: Market Size and CAGR of Various Type in the Global Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 4.4: Trends of Bivalent Inactivated Vaccine in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 4.5: Forecast for Bivalent Inactivated Vaccine in the Global Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 4.6: Trends of Trivalent Inactivated Vaccine in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 4.7: Forecast for Trivalent Inactivated Vaccine in the Global Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Chapter 5
Table 5.1: Attractiveness Analysis for the Global Reassortant Avian Influenza Virus Vaccine Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 5.3: Market Size and CAGR of Various Application in the Global Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 5.4: Trends of Piglets in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 5.5: Forecast for Piglets in the Global Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 5.6: Trends of Adults Pigs in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 5.7: Forecast for Adults Pigs in the Global Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Chapter 6
Table 6.1: Market Size and CAGR of Various Regions in the Global Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 6.2: Market Size and CAGR of Various Regions in the Global Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Chapter 7
Table 7.1: Trends of the North American Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 7.2: Forecast for the North American Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 7.3: Market Size and CAGR of Various Type in the North American Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 7.4: Market Size and CAGR of Various Type in the North American Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 7.5: Market Size and CAGR of Various Application in the North American Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 7.6: Market Size and CAGR of Various Application in the North American Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 7.7: Trends and Forecast for the United States Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 7.8: Trends and Forecast for the Mexican Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 7.9: Trends and Forecast for the Canadian Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Chapter 8
Table 8.1: Trends of the European Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 8.2: Forecast for the European Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 8.3: Market Size and CAGR of Various Type in the European Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 8.4: Market Size and CAGR of Various Type in the European Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 8.5: Market Size and CAGR of Various Application in the European Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 8.6: Market Size and CAGR of Various Application in the European Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 8.7: Trends and Forecast for the German Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 8.8: Trends and Forecast for the French Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 8.9: Trends and Forecast for the Spanish Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 8.10: Trends and Forecast for the Italian Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 8.11: Trends and Forecast for the United Kingdom Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Chapter 9
Table 9.1: Trends of the APAC Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 9.2: Forecast for the APAC Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 9.3: Market Size and CAGR of Various Type in the APAC Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 9.4: Market Size and CAGR of Various Type in the APAC Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 9.5: Market Size and CAGR of Various Application in the APAC Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 9.6: Market Size and CAGR of Various Application in the APAC Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 9.7: Trends and Forecast for the Japanese Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 9.8: Trends and Forecast for the Indian Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 9.9: Trends and Forecast for the Chinese Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 9.10: Trends and Forecast for the South Korean Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 9.11: Trends and Forecast for the Indonesian Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Chapter 10
Table 10.1: Trends of the RoW Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 10.2: Forecast for the RoW Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 10.3: Market Size and CAGR of Various Type in the RoW Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 10.4: Market Size and CAGR of Various Type in the RoW Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 10.5: Market Size and CAGR of Various Application in the RoW Reassortant Avian Influenza Virus Vaccine Market (2019-2026)
Table 10.6: Market Size and CAGR of Various Application in the RoW Reassortant Avian Influenza Virus Vaccine Market (2027-2035)
Table 10.7: Trends and Forecast for the Middle Eastern Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 10.8: Trends and Forecast for the South American Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Table 10.9: Trends and Forecast for the African Reassortant Avian Influenza Virus Vaccine Market (2019-2035)
Chapter 11
Table 11.1: Product Mapping of Reassortant Avian Influenza Virus Vaccine Suppliers Based on Segments
Table 11.2: Operational Integration of Reassortant Avian Influenza Virus Vaccine Manufacturers
Table 11.3: Rankings of Suppliers Based on Reassortant Avian Influenza Virus Vaccine Revenue
Chapter 12
Table 12.1: New Product Launches by Major Reassortant Avian Influenza Virus Vaccine Producers (2019-2026)
Table 12.2: Certification Acquired by Major Competitor in the Global Reassortant Avian Influenza Virus Vaccine Market

Companies Mentioned

  • Zoetis
  • Boehringer-Ingelheim
  • Eurovet
  • Merck Animal Health
  • Bicr
  • China Animal Husbandry Industry
  • Weike Biotechnology
  • Ringpu
  • Guangdong Winsun Bio Pharmaceutical
  • Pulike

Methodology

The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:

  • In-depth interviews of the major players in the market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.

Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.

Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

 

Loading
LOADING...